New York Life Investment Management LLC Sells 2,634 Shares of Nkarta, Inc. (NASDAQ:NKTX)

New York Life Investment Management LLC cut its stake in shares of Nkarta, Inc. (NASDAQ:NKTX) by 2.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 97,660 shares of the company’s stock after selling 2,634 shares during the quarter. New York Life Investment Management LLC owned approximately 0.20% of Nkarta worth $645,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Bourgeon Capital Management LLC purchased a new position in Nkarta during the 4th quarter worth $30,000. Forefront Analytics LLC increased its stake in shares of Nkarta by 282.5% during the third quarter. Forefront Analytics LLC now owns 39,657 shares of the company’s stock valued at $55,000 after buying an additional 29,290 shares during the period. Bleakley Financial Group LLC bought a new stake in shares of Nkarta in the fourth quarter valued at about $70,000. Simplicity Solutions LLC bought a new stake in shares of Nkarta in the fourth quarter valued at about $70,000. Finally, SG Americas Securities LLC purchased a new stake in Nkarta in the fourth quarter worth about $72,000. Institutional investors own 80.54% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. HC Wainwright reduced their price target on shares of Nkarta from $22.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Mizuho reduced their price objective on shares of Nkarta from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, March 22nd. Raymond James reaffirmed an “outperform” rating and set a $16.00 target price (up previously from $13.00) on shares of Nkarta in a research report on Friday, March 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Nkarta in a report on Wednesday, April 10th. Finally, Canaccord Genuity Group upped their price objective on Nkarta from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Nkarta currently has a consensus rating of “Buy” and an average price target of $17.83.

Insider Buying and Selling

In related news, Director Simeon George purchased 2,000,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was acquired at an average price of $10.00 per share, with a total value of $20,000,000.00. Following the completion of the acquisition, the director now owns 1,548,341 shares in the company, valued at approximately $15,483,410. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Nkarta news, insider James Trager sold 4,143 shares of Nkarta stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $12.00, for a total transaction of $49,716.00. Following the completion of the sale, the insider now owns 149,415 shares of the company’s stock, valued at approximately $1,792,980. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Simeon George acquired 2,000,000 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $20,000,000.00. Following the completion of the acquisition, the director now directly owns 1,548,341 shares of the company’s stock, valued at approximately $15,483,410. The disclosure for this purchase can be found here. 5.60% of the stock is owned by company insiders.

Nkarta Trading Down 5.9 %

Shares of NKTX opened at $6.40 on Thursday. The firm has a market cap of $316.29 million, a PE ratio of -2.67 and a beta of 0.88. Nkarta, Inc. has a 12 month low of $1.28 and a 12 month high of $16.24. The stock has a fifty day moving average price of $9.99 and a 200-day moving average price of $7.27.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.05. As a group, research analysts forecast that Nkarta, Inc. will post -2.36 EPS for the current year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.